Clairvoyant Therapeutics Revenue and Competitors

Clairvoyant is focused on short path clinical trial speed to market strategy for psilocybin psycho assisted therapy in Canada, the EU and the UK. Our seasoned clinical team has 80 years of drug development experience and was directly responsible for over 20 clinical trials. Clairvoyant is launching a phase 2b psilocybin therapy clinical trial in Alcohol Use Disorder (AUD) in 2021. We have completed our CRO RFP process, are on track with our regulatory submissions and are on schedule to start our phase 2b clinical trial in Canada and the EU in 2021. Clairvoyant's mission is to provide evidence based-psychedelic therapy to help patients live healthier and enriched lives and build stronger communities.